Research into three-dimensional genomic regulatory architecture, known as 3D genomics, offers fundamental insights into molecular controls that contribute to cellular phenotype and clinical outcomes. Oxford Biodynamics designed EpiSwitch technology — taking advantage of Agilent Microarray customization capabilities  — to interrogate key elements of this 3D architecture and provide a robust platform for discovery of statistically significant conditional genome interactions associated with specific diseases. EpiSwitch technology has demonstrated a path through Agilent-based array discovery to 3D data knowledge, providing disease insights, target identification and translation into actionable clinical tests for early diagnosis, prognosis, and response to treatment.

In this webinar, Alexandre Akoulitchev, chief scientific officer of Oxford Biodynamics, will discuss how his team developed the array design and how the customization capabilities of Agilent’s microarray platform enabled this application. He will also discuss validation of the EpiSwitch Specific Canine Blood test, a blood-based test for multiple canine oncological indications. Valentina Maran, senior product manager in the microarrays diagnostics and genomics group at Agilent, will join Akoulitchev to discuss Agilent’s role.

Learning objectives:

• 3D genomics as a fundamental biological phenomenon.
• EpiSwitch Explorer Array: Agilent-enabled tool for translation of cellular network complexities and development of robust biomarkers.
• EpiSwitch PSE and SCB: translation into practice; an accurate clinical prostate cancer detection test and a multi-cancer array-based diagnostic platform.